{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:46:50Z","timestamp":1793497610032,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Nn10 Program of Harbin Medical University Cancer Hospital","award":["Nn10py2017-04"],"award-info":[{"award-number":["Nn10py2017-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13343-x","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T04:23:57Z","timestamp":1735014237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Bingbing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"13343_CR1","doi-asserted-by":"publisher","first-page":"1374236","DOI":"10.3389\/fimmu.2024.1374236","volume":"15","author":"F Yuan","year":"2024","unstructured":"Yuan F, Hu Y, Xu F, Feng X. A review of obstructive sleep apnea and lung cancer: epidemiology, pathogenesis, and therapeutic options. Front Immunol. 2024;15: 1374236. https:\/\/doi.org\/10.3389\/fimmu.2024.1374236. Published 2024 Mar 28.","journal-title":"Front Immunol"},{"issue":"1","key":"13343_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","volume":"18","author":"Q Wang","year":"2023","unstructured":"Wang Q, G\u00fcm\u00fc\u015f ZH, Colarossi C, et al. SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol. 2023;18(1):31\u201346. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.002.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"13343_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2013.0011","volume":"11","author":"GP Kalemkerian","year":"2013","unstructured":"Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. J Natl Compr Canc Netw. 2013;11(1):78\u201398. https:\/\/doi.org\/10.6004\/jnccn.2013.0011.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"13343_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cllc.2011.05.008","volume":"13","author":"LE Gaspar","year":"2012","unstructured":"Gaspar LE, McNamara EJ, Gay EG, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer. 2012;13(2):115\u201322. https:\/\/doi.org\/10.1016\/j.cllc.2011.05.008.","journal-title":"Clin Lung Cancer"},{"issue":"28","key":"13343_CR5","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","volume":"27","author":"MA Socinski","year":"2009","unstructured":"Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27(28):4787\u201392. https:\/\/doi.org\/10.1200\/JCO.2009.23.1548.","journal-title":"J Clin Oncol"},{"issue":"10","key":"13343_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/ng.2405","volume":"44","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111\u20136. https:\/\/doi.org\/10.1038\/ng.2405.","journal-title":"Nat Genet"},{"issue":"16","key":"13343_CR7","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1200\/JCO.2018.79.2796","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(16):1645. https:\/\/doi.org\/10.1200\/JCO.2018.79.2796.","journal-title":"J Clin Oncol"},{"issue":"23","key":"13343_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"issue":"10212","key":"13343_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet"},{"key":"13343_CR10","doi-asserted-by":"publisher","first-page":"vi493","DOI":"10.1093\/annonc\/mdw389.03","volume":"27","author":"LV Sequist","year":"2016","unstructured":"Sequist LV, et al. Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). Ann Oncol. 2016;27:vi493.","journal-title":"Ann Oncol"},{"key":"13343_CR11","doi-asserted-by":"publisher","first-page":"v710","DOI":"10.1093\/annonc\/mdz264","volume":"30","author":"M Reck","year":"2019","unstructured":"Reck M, et al. IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)\u2009+\u2009carboplatin\u2009+\u2009etoposide in extensive-stage SCLC (ES-SCLC). Ann Oncol. 2019;30:v710-1.","journal-title":"Ann Oncol"},{"issue":"7","key":"13343_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17(7):883\u201395.","journal-title":"Lancet Oncol"},{"issue":"1","key":"13343_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00432-023-05544-x","volume":"150","author":"L Zhu","year":"2024","unstructured":"Zhu L, Qin J. Predictive biomarkers for immunotherapy response in extensive-stage SCLC. J Cancer Res Clin Oncol. 2024;150(1):22. https:\/\/doi.org\/10.1007\/s00432-023-05544-x. Published 2024 Jan 20.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"20","key":"13343_CR14","doi-asserted-by":"publisher","first-page":"11123","DOI":"10.3390\/ijms222011123","volume":"22","author":"V Longo","year":"2021","unstructured":"Longo V, Catino A, Montrone M, et al. What are the biomarkers for immunotherapy in SCLC? Int J Mol Sci. 2021;22(20):11123. https:\/\/doi.org\/10.3390\/ijms222011123. Published 2021 Oct 15.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"13343_CR15","doi-asserted-by":"publisher","first-page":"e13122","DOI":"10.15252\/emmm.202013122","volume":"13","author":"J Ko","year":"2021","unstructured":"Ko J, Winslow MM, Sage J. Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2021;13(1): e13122. https:\/\/doi.org\/10.15252\/emmm.202013122.","journal-title":"EMBO Mol Med"},{"key":"13343_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s43018-019-0020-z","volume":"1","author":"CA Stewart","year":"2020","unstructured":"Stewart CA, Gay CM, Xi Y, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423\u201336. https:\/\/doi.org\/10.1038\/s43018-019-0020-z.","journal-title":"Nat Cancer"},{"issue":"5","key":"13343_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"23","key":"13343_CR18","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","volume":"20","author":"B Hu","year":"2014","unstructured":"Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0442.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"13343_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/jcsm.12755","volume":"12","author":"Y Takenaka","year":"2021","unstructured":"Takenaka Y, Oya R, Takemoto N, Inohara H. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle. 2021;12(5):1122\u201335. https:\/\/doi.org\/10.1002\/jcsm.12755.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"13343_CR20","doi-asserted-by":"publisher","first-page":"726257","DOI":"10.3389\/fonc.2021.726257","volume":"11","author":"S Li","year":"2021","unstructured":"Li S, Wang T, Tong G, Li X, You D, Cong M. Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2021;11: 726257. https:\/\/doi.org\/10.3389\/fonc.2021.726257. Published 2021 Aug 26.","journal-title":"Front Oncol"},{"issue":"4","key":"13343_CR21","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1093\/oncolo\/oyad303","volume":"29","author":"SS Faria","year":"2024","unstructured":"Faria SS, Giannarelli D, Cordeiro de Lima VC, et al. Development of a prognostic model for early breast cancer integrating neutrophil to lymphocyte ratio and clinical-pathological characteristics. Oncologist. 2024;29(4):e447-54. https:\/\/doi.org\/10.1093\/oncolo\/oyad303.","journal-title":"Oncologist"},{"issue":"16","key":"13343_CR22","doi-asserted-by":"publisher","first-page":"20585","DOI":"10.18632\/aging.203449","volume":"13","author":"Y Shui","year":"2021","unstructured":"Shui Y, Li M, Su J, Chen M, Gu X, Guo W. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients. Aging. 2021;13(16):20585\u201397. https:\/\/doi.org\/10.18632\/aging.203449.","journal-title":"Aging"},{"issue":"5","key":"13343_CR23","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","volume":"40","author":"M Muscaritoli","year":"2021","unstructured":"Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898\u2013913. https:\/\/doi.org\/10.1016\/j.clnu.2021.02.005.","journal-title":"Clin Nutr"},{"issue":"2","key":"13343_CR24","doi-asserted-by":"publisher","first-page":"2288705","DOI":"10.1080\/07853890.2023.2288705","volume":"55","author":"Z Niu","year":"2023","unstructured":"Niu Z, Yan B. Prognostic and clinicopathological effect of the prognostic nutritional index (PNI) in patients with cervical cancer: a meta-analysis. Ann Med. 2023;55(2):2288705. https:\/\/doi.org\/10.1080\/07853890.2023.2288705.","journal-title":"Ann Med"},{"key":"13343_CR25","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3389\/fonc.2019.01562","volume":"9","author":"X Hua","year":"2020","unstructured":"Hua X, Long ZQ, Huang X, et al. The value of prognostic nutritional index (PNI) in predicting survival and guiding radiotherapy of patients with T1-2N1 breast cancer. Front Oncol. 2020;9: 1562. https:\/\/doi.org\/10.3389\/fonc.2019.01562. Published 2020 Jan 30.","journal-title":"Front Oncol"},{"issue":"7","key":"13343_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AC Dingemans","year":"2021","unstructured":"Dingemans AC, Fr\u00fch M, Ardizzoni A, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32(7):839\u201353. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207.","journal-title":"Ann Oncol"},{"issue":"5","key":"13343_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497\u2013530. https:\/\/doi.org\/10.6004\/jnccn.2022.0025.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"13343_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cllc.2019.07.005","volume":"20","author":"M Nishio","year":"2019","unstructured":"Nishio M, Sugawara S, Atagi S, et al. Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133). Clin Lung Cancer. 2019;20(6):469-476.e1. https:\/\/doi.org\/10.1016\/j.cllc.2019.07.005.","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"13343_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01055.","journal-title":"J Clin Oncol"},{"key":"13343_CR30","doi-asserted-by":"publisher","first-page":"1308109","DOI":"10.3389\/fimmu.2024.1308109","volume":"15","author":"M Lorenzi","year":"2024","unstructured":"Lorenzi M, Resi MV, Bonanno L, et al. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients. Front Immunol. 2024;15: 1308109. https:\/\/doi.org\/10.3389\/fimmu.2024.1308109. . Published 2024 Jan 29.","journal-title":"Front Immunol."},{"issue":"1","key":"13343_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025.","journal-title":"Immunity"},{"issue":"11","key":"13343_CR32","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503. https:\/\/doi.org\/10.1016\/S1470-2045(14)70263-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"13343_CR33","doi-asserted-by":"publisher","first-page":"17166","DOI":"10.1038\/s41598-017-17130-6","volume":"7","author":"J Yang","year":"2017","unstructured":"Yang J, Guo X, Wang M, Ma X, Ye X, Lin P. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS. Sci Rep. 2017;7(1):17166. https:\/\/doi.org\/10.1038\/s41598-017-17130-6. Published 2017 Dec 7.","journal-title":"Sci Rep"},{"issue":"3","key":"13343_CR34","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s12325-020-01229-w","volume":"37","author":"A Russo","year":"2020","unstructured":"Russo A, Russano M, Franchina T, et al. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective multicenter study. Adv Ther. 2020;37(3):1145\u201355. https:\/\/doi.org\/10.1007\/s12325-020-01229-w.","journal-title":"Adv Ther"},{"issue":"5","key":"13343_CR35","doi-asserted-by":"publisher","first-page":"e0285365","DOI":"10.1371\/journal.pone.0285365","volume":"18","author":"N Takegawa","year":"2023","unstructured":"Takegawa N, Hirabayashi T, Tanaka S, et al. The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. PLoS One. 2023;18(5): e0285365. https:\/\/doi.org\/10.1371\/journal.pone.0285365. Published 2023 May 5.","journal-title":"PLoS One"},{"issue":"11","key":"13343_CR36","doi-asserted-by":"publisher","first-page":"e31863","DOI":"10.1016\/j.heliyon.2024.e31863","volume":"10","author":"Y Sun","year":"2024","unstructured":"Sun Y, Dang Q, Ge Y, et al. Prognostic value of body mass index for first-line chemoimmunotherapy combinations in advanced non-small cell lung cancer in Chinese population. Heliyon. 2024;10(11): e31863. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31863. Published 2024 May 23.","journal-title":"Heliyon"},{"issue":"9","key":"13343_CR37","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","volume":"69","author":"L Peng","year":"2020","unstructured":"Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020;69(9):1813\u201322. https:\/\/doi.org\/10.1007\/s00262-020-02585-w.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"13343_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12876-022-02199-9","volume":"22","author":"P Ding","year":"2022","unstructured":"Ding P, Guo H, Sun C, et al. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol. 2022;22(1):121. https:\/\/doi.org\/10.1186\/s12876-022-02199-9. Published 2022 Mar 14.","journal-title":"BMC Gastroenterol"},{"key":"13343_CR39","doi-asserted-by":"publisher","first-page":"996312","DOI":"10.3389\/fonc.2023.996312","volume":"13","author":"R Fan","year":"2023","unstructured":"Fan R, Chen Y, Xu G, Pan W, Lv Y, Zhang Z. Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy. Front Oncol. 2023;13:996312. https:\/\/doi.org\/10.3389\/fonc.2023.996312. Published 2023 Apr 3.","journal-title":"Front Oncol"},{"key":"13343_CR40","doi-asserted-by":"publisher","first-page":"101538","DOI":"10.1016\/j.smim.2021.101538","volume":"57","author":"M Siwicki","year":"2021","unstructured":"Siwicki M, Pittet MJ. Versatile neutrophil functions in cancer. Semin Immunol. 2021;57:101538. https:\/\/doi.org\/10.1016\/j.smim.2021.101538.","journal-title":"Semin Immunol"},{"issue":"12","key":"13343_CR41","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/2159-8290.CD-12-0329","volume":"2","author":"M Labelle","year":"2012","unstructured":"Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012;2(12):1091\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0329.","journal-title":"Cancer Discov"},{"key":"13343_CR42","doi-asserted-by":"publisher","first-page":"603936","DOI":"10.3389\/fnut.2021.603936","volume":"8","author":"E Reber","year":"2021","unstructured":"Reber E, Sch\u00f6nenberger KA, Vasiloglou MF, Stanga Z. Nutritional risk screening in cancer patients: the first step toward better clinical outcome. Front Nutr. 2021;8:603936. https:\/\/doi.org\/10.3389\/fnut.2021.603936. Published 2021 Apr 7.","journal-title":"Front Nutr"},{"key":"13343_CR43","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.2147\/OTT.S171791","volume":"11","author":"X Zhang","year":"2018","unstructured":"Zhang X, et al. Application of weighted gene co-expression network analysis to identify key modules and hub genes in oral squamous cell carcinoma tumorigenesis. OncoTargets and therapy. 2018;11:6001\u201321. https:\/\/doi.org\/10.2147\/OTT.S171791.","journal-title":"OncoTargets and therapy"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13343-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T06:02:38Z","timestamp":1735020158000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13343-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13343"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13343-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Ethical approval for the study was obtained from the Ethics Committee of the Harbin Medical University Cancer Hospital. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"\u00a0Competing interests"}}],"article-number":"1574"}}